BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 21 2018 - 8:00AM
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) --
BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading
commercial specialty pharmaceutical company dedicated to patients
living with chronic pain, today announced that Herm Cukier, Chief
Executive Officer will present at the Rodman & Renshaw
20th Annual Global Investment Conference taking place at
the St. Regis Hotel in New York, NY.
Presentation details:
Date:
Thursday – September 6, 2018
Time:
4:15 PM Eastern Time
The presentation will be webcast live and can be accessed in
the investor section (events page) of the BDSI
website. For those who are not available to listen to the
live broadcast, a replay of the webcast will be available.
About BioDelivery Sciences
International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) a
leading commercial specialty pharmaceutical company dedicated to
patients living with chronic pain. BDSI is utilizing its
novel and proprietary BioErodible MucoAdhesive (BEMA®)
technology and other drug delivery technologies to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSI's marketed products and those in
development address serious and debilitating conditions such as
chronic pain, breakthrough cancer pain and opioid dependence.
BDSI's headquarters is in Raleigh, North
Carolina.
For more information, please visit or follow
us:
Internet: |
|
www.bdsi.com |
Facebook: |
|
Facebook.com/BioDeliverySI |
Twitter: |
|
@BioDeliverySI |
BUNAVAIL® (buprenorphine and
naloxone) buccal film (CIII) and
BELBUCA® (buprenorphine) buccal film (CIII) are
marketed in the U.S. by BioDelivery Sciences. For full
prescribing information and important safety information on BDSI
products please visit www.bdsi.com where the Company promptly
posts press releases, SEC filings, and other important
information or contact the Company at (800) 469-0261. For
full prescribing and safety information on BELBUCA, please
visit www.belbuca.com and for full
prescribing and safety information on BUNAVAIL, please
visit www.bunavail.com.
© 2018 BioDelivery Sciences International,
Inc. All rights reserved.
Contacts
Mary Coleman
Vice President, Investor and Public Relations
BioDelivery Sciences International, Inc.
919-582-9050
mcoleman@bdsi.com
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2023 to Apr 2024